File Name,Date of Petition,Identity of Submitting Entity,Representation Details,Cited Statutes or Regulations,FDA Action Commented On,Requested Action,Justification for Request
FDA-2012-P-1189-0010_Extension_Request_TMP_for_Canned_Tuna.pdf,20-Jun-12,"Bumble Bee Foods, LLC; StarKist Co.; Tri-Union Seafoods, LLC (Chicken of the Sea)",Represented by Covington & Burling LLP (Alan M. Slobodin),21 CFR 10.30; 21 CFR 130.12,Request extension of temporary marketing permit for canned tuna labeled by drained weight rather than pressed cake weight,Requested to maintain current labeling while FDA rulemaking proceeds; no consumer deception or health concerns identified,
FDA-2012-P-0119-0010_Redacted_Appeal_from_Mario_Morais.pdf,4-Jul-14,Mario Morais,N/A,21 CFR 10.75,Appeal regarding previous denial of Citizen Petition concerning desiccant labeling in pharmaceutical packaging,Request for reconsideration based on new arguments and interpretations of labeling standards,
FDA-2012-P-0260-0021_Amendment_from_Fisher_Wallace_Laboratories_LLC.pdf,7-May-14,Fisher Wallace Laboratories LLC,N/A,N/A,Request to amend citizen petition requesting FDA to reclassify cranial electrotherapy stimulators (CES) from Class III to Class II,Updated scientific rationale and regulatory arguments for reclassification of CES devices,
FDA-2012-P-0895-0004_Endo_Pharmaceuticals_Inc_Endo_Supplement.pdf,1-Nov-12,Endo Pharmaceuticals Inc.,N/A,Section 505(j)(6) of FD&C Act; 21 CFR 314.161,Supplement to original citizen petition requesting FDA find non-crush-resistant Opana ER discontinued for safety reasons and refuse/suspend ANDAs,New post-marketing data showing increased abuse and safety concerns with non-crush-resistant formulation,
FDA-2012-P-0794-0001_Piedmont_Animal_Health_Citizen_Petition.pdf,24-Aug-12,Piedmont Animal Health,N/A,21 CFR 514.1; 21 CFR 514.8; 21 CFR 514.111,Suitability petition requesting permission to submit ANADA for chewable praziquantel/pyrantel pamoate/febantel for dogs,"Differences from pioneer product (chewable form, texture, size) do not affect active ingredients or intended use",
FDA-2012-P-0270-0001_Neuro_Fitness_LLC___Citizen_Petition.pdf,23-Mar-12,Neuro Fitness LLC,N/A,21 CFR 10.30,Request FDA to reclassify cranial electrotherapy stimulators (CES) from Class III to Class II,Scientific literature and clinical evidence support reclassification for safety and effectiveness,
FDA-2012-P-0404-0001_Public_Citizen_Health_Research_Group_Citizen_Petit.pdf,11-Apr-12,Public Citizen Health Research Group,N/A,21 CFR 10.30,"Request FDA to remove propoxyphene-containing products (e.g., Darvon, Darvocet) from the market due to cardiovascular risks",Evidence of serious cardiac side effects outweighs benefits,
FDA-2012-P-0272-0001_Actavis_Inc__Attachments_1_and_2__Citizen_Petition.pdf,22-Mar-12,Actavis Inc.,N/A,21 CFR 10.30,Request that FDA refuse to approve or suspend approval of any ANDAs referencing original Opana ER formulation,Argues that changes to formulation (crush-resistant) were necessary for safety; allowing generic approval of non-crush-resistant would pose public health risk,
FDA-2012-P-0317-0001_Abbott_Laboratories_Covington_and_Burling_LLP__Cit.pdf,2-Apr-12,Abbott Laboratories (represented by Covington & Burling LLP),Covington & Burling LLP,21 C.F.R. § 10.30; Section 351 of PHSA (BPCIA),"Request that FDA not accept, file, approve, or otherwise consider biosimilar applications referencing Humira before March 23, 2010",Based on constitutional protections (Fifth Amendment takings clause) and preserving trade secrets from premature disclosure,
FDA-2012-P-0749-0001_Reference_2_Nasonex_NDA_20_762_Formulation_Develop.pdf,29-May-12,"Merck & Co., Inc.",N/A,21 CFR 10.30,Request that FDA refuse to approve any ANDA referencing Nasonex unless bioequivalence is demonstrated using the innovator's formulation,"Differences in formulation could impact clinical performance; thus, stricter bioequivalence standards needed",
FDA-2012-P-0053-0001_Lannett_Company_Inc_and_Cody_Laboratories_Inc_Alst.pdf,18-Jan-12,Lannett Company Inc. and Cody Laboratories Inc.,Alston & Bird LLP,21 CFR 10.30,Request for FDA to withdraw approval of certain generic morphine sulfate oral solutions due to bioequivalence and safety concerns,Alleged inadequacy of bioequivalence data and potential safety risks for patients,
FDA-2012-P-0298-0001_Joseph_Dedvukaj_Firm_PC_On_Behalf_of_Arena_Pharmac.pdf,20-Mar-12,Joseph Dedvukaj Firm PC on behalf of Arena Pharmaceuticals,N/A,21 CFR 10.30,Request for FDA approval of Lorcaserin for treatment of obesity,Claims sufficient evidence of safety and efficacy for new drug application approval,
FDA-2012-P-0733-0001_Jazz_Pharmaceuticals_Citizen_Petition.pdf,1-Jun-12,"Jazz Pharmaceuticals, Inc.",N/A,21 CFR 10.30,Request that FDA refuse to approve any ANDA for sodium oxybate oral solution that omits the Risk Management Program requirements,Argues that RMP requirements are necessary for safe use and should be mandatory for all generic applicants,
FDA-2012-P-0947-0001_Mallinckrodt_Inc__Citizen_Petition.pdf,12-Jul-12,Mallinckrodt Inc.,N/A,21 CFR 10.30,Request that FDA refuse to approve any ANDA for generic Exalgo unless bioequivalence is demonstrated using the approved crush-resistant formulation,Public health concerns regarding abuse potential if bioequivalence to crush-resistant formulation is not assured,
FDA-2012-P-0939-0001_Purdue_Pharma_L_P_Kleinfeld_Kaplan_and_Becker_LLP_.pdf,5-Jul-12,"Purdue Pharma L.P. (represented by Kleinfeld, Kaplan and Becker LLP)","Kleinfeld, Kaplan and Becker LLP",21 CFR 10.30,Request that FDA refuse to approve any ANDAs referencing OxyContin without demonstrating abuse-deterrent properties,Argues that removing abuse-deterrent features would pose public health risks and undermine incentives for innovation,
FDA-2012-P-0695-0006_Lorillard_Inc__Letter.pdf,11-Jun-12,"Lorillard, Inc.",N/A,21 CFR 10.30,Request to revise or withdraw sections of a Draft Guidance related to harmful and potentially harmful constituents (HPHCs) reporting requirements for tobacco products,"Argues that certain reporting requirements were premature, burdensome, and lacked statutory basis",
FDA-2012-P-0260-0001_Fisher_Wallace_Laboratories_LLC_Citizen_Petition.pdf,2-Mar-12,Fisher Wallace Laboratories LLC,N/A,21 CFR 10.30,Request that FDA reclassify cranial electrotherapy stimulators (CES) from Class III to Class II,Claims sufficient evidence of safety and effectiveness based on clinical data,
FDA-2012-P-0963-0001_Charles_J_Zimmerer_Citizen_Petition.pdf,18-Jul-12,Charles J. Zimmerer,N/A,21 CFR 10.30,Request for reconsideration of FDA's refusal to grant orphan drug designation for a specific product,Argues that the denial was based on incorrect interpretations of regulatory criteria,
FDA-2012-P-0275-0001_William_H_Lamont_Citizen_Petition.pdf,19-Mar-12,William H. Lamont,N/A,21 CFR 10.30,Request for FDA to initiate recall and conduct testing on certain nutritional supplements marketed for infants,Concerns over contamination and labeling inaccuracies potentially affecting infant health,
FDA-2012-P-0760-0001_Purdue_Pharma_L_P_Kleinfeld_Kaplan_and_Becker_LLP_.pdf,13-Jul-12,"Purdue Pharma L.P. (represented by Kleinfeld, Kaplan and Becker LLP)","Kleinfeld, Kaplan and Becker LLP",21 CFR 10.30,Request that FDA refuse to approve any ANDA for generic reformulated OxyContin unless it demonstrates comparable abuse-deterrent properties,Claims that tamper-resistance is essential for public health and generics must meet similar standards,
FDA-2012-P-0189-0001_Lannett_Company_Inc_and_Cody_Laboratories_Inc_Alst.pdf,5-Mar-12,"Lannett Company, Inc. and Cody Laboratories, Inc.",Alston & Bird LLP,21 CFR 10.30,Request that FDA recognize certain morphine sulfate oral solutions as grandfathered drugs not requiring new drug applications,Claims products meet grandfathering criteria under FDCA and have longstanding historical use without material changes,
FDA-2012-P-0137-0001_Anulex_Technologies_Inc__R_Sheridan_Consulting_LLC.pdf,10-Feb-12,"Anulex Technologies, Inc. (represented by R. Sheridan Consulting LLC)",R. Sheridan Consulting LLC,21 CFR 10.30,Request that FDA reclassify the Xclose Tissue Repair System from Class III to Class II with special controls,Argues that available clinical evidence supports safety and effectiveness under less restrictive classification,
FDA-2012-P-0275-0001_William_H_Lamont_Citizen_Petition.pdf,2-Apr-12,William H. Lamont,N/A,21 CFR 10.30,Request for FDA to take regulatory action regarding label requirements and certain drug product approvals,Argues that specific regulatory action is necessary to protect public health,
FDA-2012-P-0760-0001_Purdue_Pharma_L_P_Kleinfeld_Kaplan_and_Becker_LLP_.pdf,30-Jul-12,"Purdue Pharma L.P., Kleinfeld Kaplan and Becker LLP",Represented by legal counsel (Kleinfeld Kaplan and Becker LLP),21 CFR 314.161,Request to determine that discontinued formulations of certain drug products were withdrawn for safety reasons,Argues that old formulations pose safety concerns that justify refusal of ANDA approvals,
FDA-2012-P-0260-0001_Fisher_Wallace_Laboratories_LLC_Citizen_Petition.pdf,20-Mar-12,Fisher Wallace Laboratories LLC,N/A,21 CFR 10.30,Request for reclassification of the Fisher Wallace Stimulator from Class III to Class II,"Justifies reclassification based on safety, effectiveness, and postmarket use data",
FDA-2012-P-0963-0001_Charles_J_Zimmerer_Citizen_Petition.pdf,1-Nov-12,"Charles J. Zimmerer, Esq.",N/A,21 CFR 10.30,Request for reconsideration of FDA's refusal to grant exclusivity to a specific product,Argues that FDA misapplied its rules and the product met criteria for exclusivity,
FDA-2012-P-0103-0001_The_Feinstein_Institute_for_Medical_Reseach_North_.pdf,30-Jan-12,The Feinstein Institute for Medical Research (North Shore-LIJ Health System),N/A,21 CFR 10.30,Request for designation of a human cell and tissue-based product as a biologic,Argues the product meets statutory definitions and should be regulated as a biologic,
FDA-2012-P-0695-0007_Lorillard__Inc_Letter_with_encloure___Letter.pdf,26-Jun-12,FDA Center for Tobacco Products,Petition submitted,21 CFR 10.30,Request for enforcement discretion for premarket approval requirements under FDCA section 910(a) for two new tobacco products submitted under substantial equivalence reports,,
FDA-2012-P-1103-0001_Ikaria_Inc_Kleinfeld_Kaplan_and_Becker_LLP_Citizen.pdf,1-Nov-12,FDA Center for Drug Evaluation and Research (CDER),Citizen petition submitted,21 CFR 10.30,Request to revoke orphan drug designation granted to GeNO for nitric oxide or require clinical superiority data,,
FDA-2012-P-0295-0001_Janssen_Pharmaceuticals_Inc_Ropes_and_Gray_LLP_Cit.pdf,26-Mar-12,"Janssen Pharmaceuticals, Inc.",Represented by Ropes & Gray LLP,21 CFR 10.30,Request that FDA adopt specific bioequivalence requirements for ANDAs referencing ELMIRON (pentosan polysulfate sodium),Ensure generic versions have comparable safety and efficacy by requiring bioequivalence studies with clinical endpoints and detailed active ingredient characterization,
FDA-2012-P-1095-0001_Resveratrol_Partners_LLC_Citizen_Petition.pdf,31-May-12,"Resveratrol Partners, LLC",N/A,21 CFR 10.30,Requesting FDA to allow resveratrol dietary supplements to include specific health claims,Scientific evidence presented to support structure/function claims for resveratrol supplementation,
FDA-2012-P-1072-0001_Boehringer_Ingelheim_Pharmaceuticals_Inc_Ropes_Gra.pdf,8-Aug-12,"Boehringer Ingelheim Pharmaceuticals, Inc.",Represented by Ropes & Gray LLP,21 CFR 10.30,Request for specific bioequivalence study requirements for generic versions of Pradaxa (dabigatran etexilate),Concern about Pradaxa’s complex formulation and need for in vivo bioequivalence demonstration,
FDA-2012-P-0119-0003_Mario_Morais_Supplement.pdf,24-Apr-12,Mario Morais,N/A,21 CFR 10.30,Supplement to original citizen petition regarding regulatory actions on a drug product,,
FDA-2012-P-1103-0006_Ikaria_Inc_Kleinfeld_Kaplan_and_Becker_LLP_Supplem.pdf,13-Nov-12,"Ikaria, Inc.","Represented by Kleinfeld, Kaplan and Becker LLP",21 CFR 10.30,Supplement submission to previous citizen petition regarding nitric oxide orphan drug designation,,
FDA-2012-P-0637-0001_KV_Pharmaceutical_Company_Citizen_Petition.pdf,2-Mar-12,K-V Pharmaceutical Company,N/A,21 CFR 10.30,Request for FDA enforcement action against compounded versions of hydroxyprogesterone caproate (Makena®) products,,
FDA-2012-P-0951-0001_Endo_Pharmaceuticals_Inc_Citizen_Petition.pdf,30-May-12,"Endo Pharmaceuticals, Inc.",N/A,21 CFR 10.30,Request for FDA to deny approval of generic versions of Opana® ER that are not abuse-deterrent,,
FDA-2012-P-0387-0001_ABT_Molecular_Imaging_Inc_Citizen_Petition.pdf,18-Apr-12,"ABT Molecular Imaging, Inc.",N/A,21 CFR 10.30,Request to allow submission of ANDA for Fludeoxyglucose F18 Injection with lower strength (1–20 mCi/mL EOS),,
FDA-2012-P-0695-0012_Lorillard_Tobacco_Company_Petition_for_Reconsidera.pdf,24-Aug-12,Lorillard Tobacco Company,N/A,21 CFR 10.30,Request for reconsideration of FDA’s order finding two new tobacco products not substantially equivalent,Argues that FDA’s decision was arbitrary and capricious and did not adequately consider evidence,
FDA-2012-P-1018-0001_Mutual_Pharmaceutical_Company_Inc_Sidley_Austin_LL.pdf,23-Oct-12,"Mutual Pharmaceutical Company, Inc.",Represented by Sidley Austin LLP,21 CFR 10.30,Request for FDA to refuse acceptance of certain ANDAs referencing Sular® (nisoldipine) extended-release tablets,Argues bioequivalence standards are not met by proposed generics,
FDA-2012-P-1155-0003_Deka_Research_and_Development_Corportion__Suppleme.pdf,30-Nov-12,Deka Research and Development Corporation,N/A,21 CFR 10.30,Supplement to earlier citizen petition seeking reclassification of stair-climbing wheelchair devices,Provides additional data and responses to FDA queries to support reclassification,
FDA-2012-P-0555-0001_Teva_Pharmaceutical_Industries_Ltd_Citizen_Petitio.pdf,2-Mar-12,Teva Pharmaceutical Industries Ltd.,N/A,21 CFR 10.30,Request that FDA apply stringent standards for approving generic versions of Copaxone®,Emphasizes complexity of active ingredient and challenges of establishing sameness,
FDA-2012-P-0103-0003_Feinstein_Institute_for_Medical_Reseach_North_Shor.pdf,30-Jan-12,"Feinstein Institute for Medical Research (Thomas Chaly, Ph.D.)",N/A,NDA 22-494 (Sodium Fluoride F18 Injection); FDA regulations on ANDA amendments,Submission of an ANDA with a higher concentration than approved drug,Accept amendment to original citizen petition to include RLD labeling,"Ensure compliance with CGMP deadline (June 12, 2012)"
FDA-2012-P-0119-0005_Mario_Morais_Supplement.pdf,N/A,Mario Morais,N/A,N/A,N/A,N/A,N/A
FDA-2012-P-0496-0003_Cumberland_Pharmaceuticals_Inc_Amendment.pdf,N/A,Cumberland Pharmaceuticals Inc.,N/A,N/A,N/A,N/A,N/A
FDA-2012-P-0313-0001_Con_Vet_GmbH_and_Co_KG_Veterinary_Consulting_Group.pdf,3-May-12,Con Vet GmbH & Co KG Veterinary Consulting Group,N/A,21 CFR 10.30,Import alert on veterinary products,Request removal of Import Alert 16-129 for Polyinylpyrolidone Iodine Solution,Justification based on compliance with regulatory requirements and updated testing
FDA-2012-P-0566-0001_Citizen_Petition_Empire_State_Consumer_Project_Inc.pdf,4-Jun-12,"Empire State Consumer Project, Inc.",N/A,21 CFR 10.30,Use of polyethylene glycol (PEG 3350) products in children,"Request investigation, labeling changes, and potential withdrawal of PEG 3350 laxatives for children",Due to reports of neuropsychiatric events and other adverse events in children
FDA-2012-P-0493-0001_Leroy_Leslie_Hamilton_PhD__Change_in_Classificatio.pdf,14-May-12,"Dr. Leroy Leslie Hamilton, Ph.D.",N/A,21 CFR 860.123 (Medical Device Classification),Classification of Cranial Electrotherapy Stimulator devices,Request reclassification of CES devices from Class III to Class II,Supported by evidence of low risk and therapeutic benefit
FDA-2012-P-0184-0003_Foley_Hoag_LLP_Fresenius_Medical_Care_North_Americ.pdf,4-Apr-12,Fresenius Medical Care North America,Foley Hoag LLP,21 CFR 10.30,Policy regarding concentrated dialysate solutions,Request FDA to revise policies for sodium bicarbonate concentrate solutions,Justification based on product quality and safety improvements
FDA-2012-P-0468-0001_Cadila_Pharmaceuticals_Limited_India_Modavar_Pharm.pdf,4-May-12,Cadila Pharmaceuticals Limited / Modavar Pharmaceuticals LLC,Modavar Pharmaceuticals representative (Mr. Mayur Khamar),"21 CFR 10.20, 10.30; FDCA 505(j)",Reference Listed Drug (RLD) designation for Meclizine HCl tablets,Request designation of alternate RLD and removal of ANTIVERT if discontinued,ANTIVERT® unavailable commercially for over 12 months
FDA-2012-P-1053-0001_Citizen_Petition_from_Public_Citizen.pdf,November 2012 (approximate),Public Citizen,N/A,FDA general petition rules,Marketing approval standards,Request FDA to withdraw approval of propoxyphene-containing products,Based on cardiotoxicity and safety concerns
FDA-2012-P-1155-0001_Deka_Research_and_Development_Corporation_Change_i.pdf,4-Dec-12,DEKA Research and Development Corporation,N/A,21 CFR Part 880,Medical device classification,Request reclassification of HomeChoice PRO Peritoneal Dialysis System accessory from Class III to Class II,Based on low risk and intended use
FDA-2012-P-0040-0001_Electronic_Version_Fischer_Surgical_Inc_Citizen_Pe.pdf,29-Dec-11,Fischer Surgical Inc.,"Craig Fischer, CEO",21 CFR 10.33,NSE (Not Substantially Equivalent) letter issued for NCI Spatula,Acceptance of NCI Spatula as substantially equivalent to Endoserter (K090626),Overlooked endotoxin compliance; functionality demonstrated; no lower limit required
FDA-2012-P-0299-0007_Supplement_from_Front_Range_Equine_Rescue_and_The_.pdf,10-Mar-14,Front Range Equine Rescue and The Humane Society of the United States,Schiff Hardin LLP (Bruce A. Wagman),21 U.S.C. § 342(a)(4); 21 U.S.C. § 342(a)(2)(C)(ii),Rulemaking regarding adulterated horse meat,Supplement to petition requesting action against adulterated horse meat from American horses,Lack of treatment records makes horse meat adulterated; violations of FDCA
FDA-2012-P-1007-0001_Public_Citizen_Citizen_Petition.pdf,19-Sep-12,Public Citizen,N/A,21 C.F.R. § 20.49(d); FOIA regulations (5 U.S.C. § 552),FOIA policy and minor deletions,Revoke 21 C.F.R. § 20.49(d) and revise FDA FOIA practices,Policy inconsistent with FOIA and HHS regulations; harms FOIA requesters
FDA-2012-P-1252-0001_Center_for_Food_Safety_CFS_Citizen_Petition.pdf,5-Dec-12,Center for Food Safety (CFS),N/A,21 CFR 10.30,Food additive petition process,Request FDA to issue a new rule banning arsenic-based drugs in animal feed,Scientific evidence linking arsenic to cancer and other health risks
FDA-2012-P-0872-0051_Supplement_from_the_Handcrafted_Soap_and_Cosmetic_.pdf,Oct-12,Handcrafted Soap and Cosmetic Guild,N/A,"21 CFR 701.3, 21 U.S.C. 321(g)(1)",Labeling requirements for handcrafted soaps,Supplemental submission urging FDA to distinguish handcrafted soaps from cosmetics,Handcrafted soaps not intended to affect body structure or function; soaps are not cosmetics
FDA-2012-P-1009-0001_Pfizer_Inc_Covington_and__Burling_LLP__Citizen_Pet.pdf,28-Aug-12,Pfizer Inc.,Covington & Burling LLP,21 CFR 10.30,Labeling for generic versions of Vfend (voriconazole),Request FDA to require generic voriconazole applicants to conform to Vfend labeling until FDA updates it,To maintain consistency and avoid confusion during labeling transition
FDA-2012-P-0632-0001_Citizen_Petition_from_Par_Pharmaceutical.pdf,2-Apr-12,"Par Pharmaceutical, Inc.",N/A,21 CFR 10.30,Labeling for methylphenidate ER tablets,Request FDA to ensure generic methylphenidate ER products remain therapeutically equivalent to Concerta,To preserve therapeutic equivalence standards and prevent patient confusion
FDA-2012-P-1112-0005_Letter_from_Nobel_Laboratories_LLC.pdf,15-Oct-12,"Nobel Laboratories, LLC",N/A,21 CFR 10.30,Suitability petition for Ibuprofen Orally Disintegrating Tablets 100 mg,Request approval for ANDA suitability petition for a new dosage form,Provides bioequivalence and scientific rationale for suitability
FDA-2012-P-1267-0001_Xspire_Pharma_LLC_Citizen_Petition.pdf,26-Dec-12,"Xspire Pharma, LLC","FaMundy, President and CEO","Cited: 21 CFR 314.93, 21 CFR 25.31(a), 21 CFR 10.30(b)",Approval to submit ANDA with new strength for Azdone™ (hydrocodone bitartrate and aspirin tablets),"Allow filing of ANDA for Aspirin, Hydrocodone Bitartrate Tablets, 325 mg / 5 mg",Request based on identical active moiety (hydrocodone) and strength adjustment permitted under regulation; product not withdrawn for safety/efficacy
FDA-2012-P-0545-0001_Pfizer_Inc_Citizen_Petition.pdf,N/A,Pfizer Inc.,N/A,21 CFR Part 10,Request to deny approval of specific ANDAs,for generic versions of a drug,Listed reasons for concerns about therapeutic equivalence
FDA-2012-P-0499-0001_Jazz_Pharmaceuticals_Inc_Citizen_Petition.pdf,N/A,"Jazz Pharmaceuticals, Inc.",N/A,21 CFR 10.30,Concerns about approval of certain generics,Requesting delay or additional requirements for generics to ensure therapeutic equivalence,Evidence that the reference product has complex release mechanisms
FDA-2012-P-1267-0001_Xspire_Pharma_LLC_Citizen_Petition.pdf,26-Dec-12,"Xspire Pharma, LLC","FaMundy, President and CEO","21 CFR 314.93, 21 CFR 25.31(a)",ANDA Suitability Petition for Azdone (Aspirin and Hydrocodone Bitartrate) tablets,Approval to submit an ANDA with a different strength (325 mg/5 mg),"Submission under FDA regulations allowing strength changes, supporting documents attached"
FDA-2012-P-0661-0001_Citizen_Petition_from_Sandoz_Inc_.pdf,5-Jul-12,Sandoz Inc.,N/A,21 CFR 10.30,Request regarding ANDA submission for generic teriparatide injection,Seek FDA to require REMS-compliant product labeling to match FORTEO labeling,Ensures patient safety through identical REMS compliance
FDA-2012-P-1170-0001_Cephazone_Pharma_LLC_Citizen_Petition.pdf,12-Nov-12,Cephazone Pharma LLC,N/A,21 CFR 10.30,Request suitability petition for Excenel RTU (Ceftiofur hydrochloride) generic version,Approve new strength generic with certain differences,Scientific data supports equivalence despite formulation differences
FDA-2012-P-0279-0001_Lupin_Pharmaceutical__Inc____Citizen_Petition.pdf,16-Mar-12,"Lupin Pharmaceuticals, Inc.",N/A,21 CFR 10.30,Request determination that Teva forfeited 180-day exclusivity for Avapro generics,Request FDA to allow other generic entry,Factual and legal analysis of forfeiture events and ANDA amendments
FDA-2012-P-0292-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,14-Mar-12,"Lachman Consultant Services, Inc.",N/A,21 CFR 10.30,ANDA suitability petition for Hydrocodone Bitartrate and Acetaminophen Tablets,Request FDA to approve ANDA suitability petition for different dosage strength,Scientific justification that change in strength does not affect safety and efficacy
FDA-2012-P-0737-0001_Actient_Pharmaceuticals_Citizen_Petition.pdf,19-Jun-12,Actient Pharmaceuticals LLC,N/A,21 CFR 10.30,Request regarding marketing status of Testopel® Pellets,Seek FDA to take enforcement action against unapproved testosterone pellet products,Ensure market integrity and protect public health
FDA-2012-P-1265-0001_Indicus_Pharma_LLC_Citzen_Petition.pdf,17-Dec-12,Indicus Pharma LLC,N/A,21 CFR 314.93,Orange Book listing of Meclizine Hydrochloride Tablets,"Assign second RLD (Reference Listed Drug) for Meclizine Hydrochloride 12.5 mg, 25 mg, and 50 mg",Scientific rationale supporting that new RLD assignment would facilitate ANDA submissions
FDA-2012-P-1052-0001_James_Flory_MD_MSCE_et_al_New_York_Presbyterian_Ho.pdf,9-Oct-12,"James Flory, MD, MSCE, et al. (New York Presbyterian Hospital)",N/A,21 CFR 10.30,Boxed Warning and labeling for Metformin,Remove boxed warning for lactic acidosis and revise contraindications,"Updated evidence shows metformin's lactic acidosis risk is extremely low, especially in mild renal impairment"
FDA-2012-P-0271-0001_Lachman_Consultant_Services_Inc__Citizen_Petition.pdf,12-Mar-12,"Lachman Consultant Services, Inc.",N/A,21 CFR 314.93,ANDA suitability petition for new strength hydrocodone bitartrate and acetaminophen tablets,Request FDA approval to submit an ANDA for a new intermediate strength,Scientific justification that intermediate strength maintains same safety and efficacy profile
FDA-2012-P-0617-0004_Combination_Products_Coalition_Epstein_Becker_and_.pdf,8-Jun-12,"Combination Products Coalition (Epstein Becker & Green, P.C.)","Attorney representation by Epstein Becker & Green, P.C.",21 CFR 3.2(e),FDA jurisdiction over combination products,Request FDA to provide clearer criteria and a formal process for classification,Unclear classification leads to regulatory uncertainty affecting product development
FDA-2012-P-0583-0001_Pfizer_Inc_Citizen_Petition.pdf,6-Jun-12,Pfizer Inc.,"Geoffrey Levitt, Senior Vice President & Associate General Counsel","21 U.S.C. 351, 355; 21 C.F.R. 10.30",ANDA approvals for Lyrica generics,Refusal to approve ANDAs with minimum isomeric impurity levels; require recertification for changes,"Request based on scientific standards for impurity specifications, risk of inappropriate regulatory approval, and impact on patent litigation."
FDA-2012-P-0857-0007_Sheller_P_C_Amendment.pdf,27-Aug-12,"Sheller, P.C.",N/A,"21 U.S.C. §§ 352, 321; 21 C.F.R. §§ 10.30, 7.45",Pediatric indication and labeling for Risperdal and related products,Revoke pediatric indication or require black box warning for Risperdal/Invega products,"Concerns about insufficient safety data, hyperprolactinemia, gynecomastia, mislabeling risks, inadequate physician guidance."
FDA-2012-P-0436-0001_Lupin_Pharmaceuticals_Inc_Citizen_Petition.pdf,3-May-12,"Lupin Pharmaceuticals, Inc.","Leslie Sands, Director – Regulatory Affairs (USA)",21 CFR 10.30; 21 CFR 314.94,Orange Book listing for Meclizine Hydrochloride Tablets,Amend Orange Book to assign Par Pharm and Amneal Pharms as second reference listed drugs,Justification based on market availability and regulatory principles regarding therapeutic equivalence.
FDA-2012-P-0298-0010_Joseph_Dedvukaj_Firm_PC_on_Behalf_of_Arena_Pharmac.pdf,27-Mar-12,"Various physicians represented by Joseph Dedvukaj Firm, P.C.","Dr. Peter Le, Dr. Francis Le, Dr. Mark Le, others",21 CFR 10.30,Approval of Arena Pharmaceuticals’ Lorcaserin 10 mg BID and QD formulations,"Request for approval of Lorcaserin based on evidence of safety, efficacy, and the unmet need in obesity treatment.",
FDA-2012-P-0052-0001_Lannett_Company_Inc__Citizen_Petition.pdf,10-Jan-12,"Lannett Company, Inc.","Arthur Bedrosian, President and CEO",21 CFR 201.57(c)(8)(i); 21 CFR 10.30; Section 505(o)(4) of FDCA,Warning label for Phentermine HCl products regarding combination with Topiramate,Add warning about unproven safety of combining Phentermine and Topiramate,Concerns over serious adverse effects based on advisory committee findings and existing safety data.
FDA-2012-P-0983-0001_Sheppard_Mullin_Richter_and_Hampton_LLP_Citizen_Pe.pdf,13-Sep-12,Sheppard Mullin Richter & Hampton LLP,"Peter S. Reichertz, Esq. (Sheppard Mullin)",Section 505(j)(2)(C) of the FD&C Act; 21 CFR §§ 10.30 and 314.93,ANDA Suitability Petition for Potassium Acetate Injection,"Approval to submit an ANDA for Potassium Acetate Injection, USP, 2 mEq/mL, 100 mL glass vial",Proposed strength differs only in total drug content; otherwise matches the RLD; provides larger vial for hospital/pharmacy use.
FDA-2012-P-0200-0001_PharmaForce_Inc_Citizen_Petition.pdf,29-Feb-12,"PharmaForce, Inc.","Marilyn A. Friedly (Director, Regulatory Affairs)",Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30,ANDA Suitability Petition for Doxorubicin Hydrochloride Injection,"Approval to submit an ANDA for Doxorubicin Hydrochloride Injection, 2 mg/mL (100 mg/50 mL) vial",Change in total drug content (not concentration) to provide flexibility and minimize waste.
FDA-2012-P-0298-0011_Joseph_Dedvukaj_Firm_PC_on_Behalf_of_Arena_Pharmac.pdf,28-Mar-12,"Joseph Dedvukaj Firm, P.C. on behalf of Arena Pharmaceuticals, Inc.","Multiple Physicians (Dr. Robert A. Rostock, Dr. Ardeis Scott, Dr. Patrick James Bennett, Dr. Jay R. Miller)",21 CFR § 10.30,Request for approval of Lorcaserin 10 mg BID and 10 mg QD,Approval of Arena Pharmaceuticals' obesity drug Lorcaserin (10 mg BID and QD) based on trial results (BLOOM-DM study),Lorcaserin met weight loss endpoints; emphasized benefits for diabetic and obese patients; warned of research setbacks if not approved.
FDA-2012-P-0617-0006_Letter_from_Combination_Products_Coalition_Epstein.pdf,29-Aug-14,Combination Products Coalition (CPC),Bradley Merrill Thompson (on behalf of CPC),21 CFR § 10.30,Citizen Petition requesting improvement of FDA's guidance development process,Meeting request to discuss delays and propose reforms,Highlighting impact of delays on innovation; pushing for updates to Intercenter Agreements and faster guidance issuance.
FDA-2012-P-1107-0001_FzioMed_Inc_Hogan_Lovells_US_LLP_Citizen_Petition.pdf,5-Nov-12,"FzioMed, Inc.","Janice Hogan, Esq. (Hogan Lovells US LLP)",Section 515(g)(2)(a) and Section 562 of the FD&C Act; 21 CFR 10.33,Petition for reconsideration of denial of PMA for Oxiplex/SP Gel,Request reversal of PMA denial and approval based on existing clinical evidence and foreign approvals.,
FDA-2012-P-0984-0001_Sheppard_Mullin_Richter_and_Hampton_LLP_Citizen_Pe.pdf,13-Sep-12,Sheppard Mullin Richter & Hampton LLP,"Peter S. Reichertz, Esq.",Section 505(j)(2)(C) of the FD&C Act; 21 CFR §§ 10.30 and 314.93,ANDA Suitability Petition for Potassium Acetate Injection,"Approval to submit an ANDA for Potassium Acetate Injection, USP 2 mEq/mL, 20 mL glass vial",Change in container from plastic to glass for better stability without changing concentration or formulation.
FDA-2012-P-0554-0003_Lupin_Pharmaceuticals_Inc_Withdrawal.pdf,25-Jun-12,"Lupin Pharmaceuticals, Inc.",Leslie Sands (Director - Regulatory Affairs),21 CFR 10.25 and 10.30,Request to withdraw previous Citizen Petition concerning LOFIBRA (Fenofibrate Tablets),Withdrawal requested because the product was relisted as active in the Orange Book.,
FDA-2012-P-0142-0001_Lannett_Company_Inc_Citizen_Petition.pdf,3-Feb-12,"Lannett Company, Inc.",Arthur P. Bedrosian (President and CEO),Section 505(j) of the FD&C Act; 21 CFR 314.93,Request to allow supplement submission to ANDA 201407 for new strength 50 mg/25 mg of Triamterene and Hydrochlorothiazide Capsules,Request to avoid a separate ANDA and submit as a supplement to save FDA resources; same active ingredients and similar specifications.,
FDA-2012-P-0993-0003_Sheppard_Mullin_Richter_and_Hampton_LLP_Withdrawal.pdf,16-Nov-12,Sheppard Mullin Richter & Hampton LLP,"Peter S. Reichertz, Esq.","Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.20, 10.30, and 314.93",Withdrawal of ANDA Suitability Petition for Atropine Sulfate Injection,Withdrawal because FDA would consider glass ampules under earlier related petition,Duplicate effort since FDA is reviewing an existing petition; no need for separate review.
FDA-2012-P-1189-0011_Bumble_Bee_ChickenoftheSea_StarKist_TMP_Applicatio.pdf,12-Oct-11,"Bumble Bee Foods, LLC; StarKist Co.; Tri-Union Seafoods, LLC",Robert A. Hahn (Olsson Frank Weeda Terman Matz PC),21 CFR § 130.17,Application for Temporary Marketing Permit (TMP) for Canned Tuna products,Request for TMP to test market canned tuna products deviating from standard of identity,To allow innovation and labeling improvements; align U.S. standard with global practices; encourage seafood consumption per Dietary Guidelines.
FDA-2012-P-0747-0001_Leroy_Leslie_Hamilton_PhD_Citizen_Petition.pdf,3-Jul-12,"Leroy Leslie Hamilton, Ph.D.","Leroy Leslie Hamilton, Ph.D.",21 CFR 10.30,Request for investigation into FDA Form 3429 (Device Classification Form),Request impartial review of whether FDA Form 3429 conforms to Class III statutory definition,"Form allegedly flawed, leading to device misclassifications; calls for corrections and transparency."
FDA-2012-P-1107-0026_Letter_from_FzioMed_Inc_Hogan_Lovells_US_LLP.pdf,6-Mar-14,"FzioMed, Inc.",Janice M. Hogan (Hogan Lovells US LLP),21 CFR 10.33,Comments on Draft Statement of Issues for Oxiplex® Dispute Resolution Panel,"Requested edits to better frame key dispute points, particularly statistical analysis and regulatory interpretation",Clarify subgroup analysis methodology; emphasize safety established; ensure Panel's fair assessment.
FDA-2012-P-0637-0005_KV_Pharmaceutical_Company_Reply_Comment.pdf,12-Nov-12,KV Pharmaceutical Company,N/A,Section 505(q) of the FD&C Act; 21 CFR § 10.30,Response to comments on Citizen Petition regarding Delalutin,Opposing approval of ANDAs for hydroxyprogesterone caproate referencing Delalutin,"Maintains safety concerns, lack of modern efficacy evidence, and risk to orphan drug exclusivity for Makena."
FDA-2012-P-0904-0316_Citizens_for_Health_CFH_Supplement_Amendment_to_HF.pdf,5-Aug-14,Citizens for Health,N/A,21 CFR Parts 12-16; FD&CA §402(a)(2)(C),Amendment and supplement to Citizen Petition on HFCS (High Fructose Corn Syrup),"Label fructose concentration (e.g., HFCS-42, HFCS-55) on products and enforce action against excess fructose concentrations",Consumers deserve clear labeling on fructose content; address health risks and regulatory compliance.
FDA-2012-P-1107-0028_Letter_from_FzioMed__Inc_Nogan_Lovells_US_LLP_to_F.pdf,18-Mar-14,"FzioMed, Inc.",Janice M. Hogan (Hogan Lovells US LLP),21 CFR 10.33,Comments on revised Draft Statement of Issues for Oxiplex® Dispute Resolution Panel,Argues that safety of Oxiplex is already established and shouldn't be an open issue,"Supports with historical FDA meetings, clinical studies, and international postmarket experience."
FDA-2012-P-0932-0001_Noven_Pharmaceuticals_Inc_Citizen_Petition.pdf,24-Aug-12,"Noven Pharmaceuticals, Inc.",N/A,Section 505(q) of the FD&C Act; 21 CFR § 10.30,Request to impose stricter bioequivalence standards for generic Daytrana patches,"Require additional bioequivalence, usability, heat effect studies, and residual drug load limits",Differences in transdermal delivery demand higher scrutiny to ensure patient safety.
FDA-2012-P-0050-0001_Arent_Fox_LLP_Citizen_Petition.pdf,10-Jan-12,Arent Fox LLP,Wayne H. Matelski,21 CFR 314.161; 21 CFR 10.25(a) and 10.30,Request to determine voluntary withdrawal of Jenloga™ and Kapvay™ (clonidine hydrochloride) was not for safety or effectiveness reasons,Allow submission and approval of ANDAs referencing Jenloga™ or Kapvay™,Drugs were withdrawn for economic or strategic reasons; no safety or efficacy concerns.
FDA-2012-P-0583-0008_Pfizer_Inc_Supplement.pdf,17-Oct-12,Pfizer Inc.,Geoffrey Levitt (Senior Vice President & Associate General Counsel),21 CFR 10.30,"Supplement to Citizen Petition regarding pregabalin ANDAs with ""not less than"" impurity specifications","Request FDA to deny amendments allowing ""not less than"" (NLT) impurity specs and enforce stricter standards",Court decision confirms infringement even with NLT impurity levels; Pfizer argues NLT specs are unlawful and inappropriate.
FDA-2012-P-1160-0001_Steven_A_Zecola_Citizen_Petition_Redacted_Version.pdf,15-Nov-12,Steven A. Zecola,Steven A. Zecola,21 CFR 10.30,"Request FDA to withdraw approval of ACT chemotherapy (Adriamycin, Cytoxan, Taxol) for BRCA1-related breast cancer patients",Withdraw ACT chemotherapy for BRCA1 triple-negative patients and recognize them as a distinct subgroup,Scientific studies show ACT chemotherapy may be disproportionately harmful to BRCA1 patients; better alternatives (PARP/platinum) exist.
FDA-2012-P-0061-0001_Lannett_Company_Inc__Citizen_Petition.pdf,16-Jan-12,"Lannett Company, Inc.",Arthur Bedrosian (President & CEO),Section 505(j) of the FD&C Act; 21 CFR 314.93,Request to submit a supplement to ANDA 201407 for 50 mg/25 mg Triamterene and Hydrochlorothiazide Capsules,Allow supplement submission instead of filing a new ANDA to save resources,50/25 mg strength already approved elsewhere; minor differences; avoids duplication.
FDA-2012-P-0857-0001_Citizen_Petition_from_Sheller_P_C_Law_Offices.pdf,27-Jul-12,"Sheller, P.C.","Lawrence J. Deutsch (Partner, Sheller P.C.)","21 CFR §§ 10.30 and 7.45; FDCA §§ 352, 321","Request to revoke pediatric indications for Risperdal, generic risperidone, and Invega, or alternatively impose black box warnings on labels",Protect pediatric patients from insufficiently studied risks of prolactin-related adverse events such as gynecomastia and endocrine disruption.,
FDA-2012-P-1029-0003_Amendment_from_Lachman_Consultant_Services_Inc.pdf,17-Oct-12,"Lachman Consultant Services, Inc.","Diana Sloane, R.Ph.",21 CFR 10.30,Amendment to Citizen Petition regarding Valrubicin Solution for Intravesical Instillation,Submission of proposed package insert labeling in support of suitability petition for Valrubicin generic.,
FDA-2012-P-0943-0001_Sunovion_Pharmaceuticals_Inc_Covington_and_Burling.pdf,29-Aug-12,"Sunovion Pharmaceuticals, Inc.",Covington & Burling LLP,Section 505(q) of the FD&C Act; 21 CFR 10.30,Citizen Petition challenging Dr. Reddy’s ANDA for generic Lunesta,Request FDA to refuse approval unless impurity limits for (R)-isomer are lowered to NMT 0.30%; concerns over public health and patent infringement.,
FDA-2012-P-0515-0001_Osmotica_Pharmaceutical_Corporation__Citizen_Petit.pdf,17-May-12,Osmotica Pharmaceutical Corp.,N/A,Section 505(q) of the FD&C Act; 21 CFR §§ 10.20 and 10.30,Request to refuse approval of Sun Pharma’s ANDA supplement for Venlafaxine HCl ER Tablets if tablet size is considerably larger than RLD,Concerns about patient safety and compliance due to difficulty swallowing larger tablets; potential impact on efficacy.,
FDA-2012-P-1068-0003_Ben_Venue_Laboratories_Withdrawal.pdf,15-Feb-13,"Ben Venue Laboratories, Inc.","Amy Schutte (Associate Director, Regulatory Affairs)",Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93 and 10.30,Request to withdraw Suitability Petition regarding Ondansetron in 5% Dextrose Injection,Withdrawal due to safety concerns communicated by FDA regarding the proposed strength.,
FDA-2012-P-1000-0001_CUSTOpharm_Inc_Citizen_Petition.pdf,11-Sep-12,"CUSTOpharm, Inc.",N/A,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30,Request for determination that Dapiprazole Hydrochloride Ophthalmic Solution was not withdrawn for safety or effectiveness,No evidence suggesting withdrawal for safety or effectiveness reasons; request eligibility for ANDA submission.,
FDA-2012-P-0986-0004_Luitpold_Pharmaceuticals_Inc_Amendment.pdf,Oct-13,"Luitpold Pharmaceuticals, Inc.",N/A,21 CFR 10.30,"Amendment related to Atropine Sulfate Injection, USP",Request to revise or supplement prior submissions concerning ANDA suitability for Atropine Sulfate Injection.,
FDA-2012-P-0818-0001_Physicians_for_Responsible_Opioid_Prescribing_Citi.pdf,25-Jul-12,Physicians for Responsible Opioid Prescribing (PROP),"Andrew Kolodny, M.D. and others",21 CFR 10.20 and 10.30,"Request to modify opioid labeling to remove ""moderate pain"" indication, set dosage and duration limits for non-cancer pain",Responds to rising opioid addiction and overdose risks; argues current labeling promotes unsafe use.,
FDA-2012-P-0292-0004_Lachman_Consultant_Services_Inc_Withdrawal.pdf,13-Nov-12,"Lachman Consultant Services, Inc.","Janulis, A.C.",21 CFR 10.30,Request to withdraw Citizen Petition regarding Opana ER designation as RLD,"Request withdrawal because the requested action (designation as RLD) was already completed by FDA, rendering the petition moot.",
FDA-2012-P-1128-0005_Dechra_Ltd_Withdrawal_of_Citizen_Petition_CP_2.pdf,19-Nov-12,Dechra Ltd.,Susan Longhofer,21 CFR 10.30,Request to withdraw Suitability Petition for scoring changes in veterinary pimobendan tablets,Withdrawal without prejudice; no specific safety or efficacy issues mentioned.,
FDA-2012-P-1087-0001_Warner_Chilcott_Company_LLC_Citizen_Petition.pdf,24-Oct-12,"Warner Chilcott Company, LLC","Alvin Howard (Senior Vice President, Regulatory Affairs)","Sections 505(j) and 505(q) of the FD&C Act; 21 CFR §§ 10.30, 314.94, and 320.21",Request FDA to clarify and establish criteria for demonstrating bioequivalence for mesalamine delayed-release tablets and apply them to ANDAs referencing Asacol or Asacol HD,Ensure stricter standards for bioequivalence to protect efficacy and therapeutic integrity due to high variability of mesalamine absorption.,
FDA-2012-P-0895-0007_Endo_Pharmaceuticals_Supplement_Cover_Sheet.pdf,14-Feb-13,Endo Pharmaceuticals Inc.,"Robert Barto (Vice President, Regulatory Affairs)",Section 505(q) of the FD&C Act; 21 CFR 10.30,Supplement to Citizen Petition regarding Opana ER and generic oxymorphone products,Request confidential consideration of additional documents submitted in support of prior petition regarding product safety and abuse deterrence.,
FDA-2012-P-1004-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,14-Sep-12,Sheppard Mullin Richter & Hampton LLP,"Peter S. Reichertz, Esq.","Section 505(j)(2)(C) of the FD&C Act; 21 CFR §§ 10.20, 10.30, and 314.93","ANDA Suitability Petition for Magnesium Sulfate Injection, USP 50%, in a 50 mL glass vial",Request approval for a different container size and material compared to the RLD (from plastic 2mL/10mL to glass 50mL vial).,
FDA-2012-P-1107-0033_Oxiplex__SP_Gel__FzioMed__Incorporated_s_Petition_.pdf,14-May-14,"FzioMed, Inc.",N/A,Section 515(g)(2) of the FD&C Act,Petition for review of FDA’s denial of PMA for Oxiplex/SP Gel,Request reconsideration through Medical Devices Dispute Resolution Panel; arguing sufficiency of clinical evidence for approval.,
FDA-2012-P-0895-0001_Endo_Pharmaceuticals_Inc_Citizen_Petition.pdf,10-Aug-12,Endo Pharmaceuticals Inc.,N/A,Sections 505(j) and 505(q) of the FD&C Act; 21 CFR §§ 10.30 and 314.161,Request FDA to determine discontinued Opana ER formulation withdrawn for safety and prevent generic approval,Argues non-crush-resistant Opana ER was discontinued for safety reasons and generics should not rely on it.,
FDA-2012-P-0986-0005_Second_Amendment_to_ANDA_Suitability_Petition_from.pdf,2-Mar-18,"Luitpold Pharmaceuticals, Inc.",Raenel Gibson (Regulatory Affairs Director),"Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.20, 10.30, and 314.93","Second Amendment to ANDA Suitability Petition for Atropine Sulfate Injection, USP",Request to allow ANDA submission for new strengths (1.0 mg/mL and 0.4 mg/mL) based on updated labeling alignment with RLD; support continued supply for medically necessary use.,
FDA-2012-P-1189-0015_Canned_Tuna_Deviating_From_the_Standard_of_Identit.pdf,28-Dec-21,"Bumble Bee Foods, LLC and StarKist Seafood Co.",N/A,21 CFR 130.17,Amendment of Temporary Marketing Permits for Canned Tuna Products,Request to add manufacturing locations and increase test product quantity for canned tuna products deviating from standard of identity in 21 CFR 161.190.,
FDA-2012-P-0499-0003_Jazz_Pharmaceuticals_Inc_Amendment.pdf,18-Jun-12,"Jazz Pharmaceuticals, Inc.","Philip J. Horhamp (Vice President, Strategic Operations)",21 CFR 10.30,Amendment to Citizen Petition regarding Xyrem (sodium oxybate) bioequivalence requirements,Request to ensure FDA publishes bioequivalence study requirements in Orange Book and requires in vivo studies for ANDAs referencing Xyrem.,
FDA-2012-P-1026-0001_Synergy_Health_Concepts_Inc_C_Humphrey_and_Associa.pdf,24-Sep-12,"Synergy Health Concepts, Inc.","Christine M. Humphrey, Esq.",21 CFR 10.35,Petition for Stay of Action regarding disclosure of FDA Warning Letters,Request to stay public disclosure of Warning Letters regarding investigational device studies at Synergy Health due to pending administrative review.,
FDA-2012-P-1189-0001_Canned_Tuna_Deviating_from_Identity_Standard__Temp.pdf,10-Jan-13,Chicken of the Sea International,N/A,21 CFR 130.17,"Temporary permit for marketing ""no drain canned tuna"" deviating from U.S. standard of identity",Allow test marketing to measure consumer acceptance and commercial feasibility; products deviate by minimal liquid addition and seasoning ingredients.,
FDA-2012-P-1189-0014_Canned_Tuna_Deviating_From_the_Standard_of_Identit.pdf,5-Mar-21,StarKist Seafood Company,N/A,21 CFR 130.17,Amendment to temporary marketing permit for canned tuna products,Permit amended to add three new manufacturing locations and increase quantity of test product; continues consumer testing.,
FDA-2012-P-1189-0004_Canned_Tuna_Deviating_From_Identity_Standard__Temp.pdf,7-Mar-16,"Bumble Bee Foods LLC, Chicken of the Sea International, StarKist Seafood Company",N/A,21 CFR 130.17,Extension of temporary permits for market testing canned tuna deviating from standard,Extension allows continued consumer testing in support of petition to amend the canned tuna standard of identity.,
FDA-2012-P-0649-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,18-Jun-12,"Lachman Consultant Services, Inc.",Robert W. Pollock,21 CFR 10.30 and 21 CFR 314.161,"Request for determination whether Questran (Cholestyramine for Oral Suspension, USP) was withdrawn for safety or effectiveness reasons",Allow ANDA submissions for Questran if withdrawal was not for safety reasons.,
FDA-2012-P-0507-0001_Cumberland_Pharmaceutical_Inc_Covington_and_Burlin.pdf,18-May-12,Cumberland Pharmaceuticals Inc.,Peter O. Safir (Covington & Burling LLP),Section 505(j) of the FD&C Act; 21 CFR 10.30,Request FDA not approve ANDAs for Acetadote® formulations containing EDTA,Argues EDTA poses safety concerns; Acetadote reformulated to remove EDTA at FDA’s request.,
FDA-2012-P-1189-0016_Canned_Tuna_Deviating_From_Identity_Standard__Amen.pdf,21-Dec-22,StarKist Co.,N/A,21 CFR 130.17,Amendment to temporary marketing permit for canned tuna products,Adds RD Foods Americas as an additional manufacturing location for test product; continues consumer acceptance testing :contentReference[oaicite:0]{index=0}.,
FDA-2012-P-1189-0002_Canned_Tuna_Deviating_From_Identity_Standard__Temp.pdf,20-Jun-14,Bumble Bee Foods LLC; Chicken of the Sea International; StarKist Seafood Company,N/A,21 CFR 130.17,Temporary permit for canned tuna deviating from standard of identity,Permit issued to allow market testing of canned tuna products with minor deviations to measure consumer acceptance and commercial feasibility :contentReference[oaicite:1]{index=1}.,
FDA-2012-P-0583-0004_Pfizer_Inc_Supplement.pdf,26-Jun-12,Pfizer Inc.,Geoffrey Levitt (Senior Vice President & Associate General Counsel),21 CFR 10.30,Supplement to Citizen Petition regarding pregabalin ANDA impurity specifications,"Request FDA to reject ""not less than"" impurity specifications proposed by Actavis for generic pregabalin; maintain safety and quality standards :contentReference[oaicite:2]{index=2}.",
FDA-2012-P-0754-0001_North_American_Olive_Oil_Association_Citizen_Petit.pdf,9-Jul-12,North American Olive Oil Association,N/A,21 CFR 130,Request to enhance and reaffirm standard of identity for olive oil and olive-pomace oil,Request FDA to adopt USDA and Codex standards for olive oil to ensure authenticity and consumer protection :contentReference[oaicite:3]{index=3}.,
FDA-2012-P-0479-0001_Natco_Pharma_Limited__Citizen_Petition.pdf,8-May-12,Natco Pharma Limited,N/A,"Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.20, 10.30, and 314.93",Request for Suitability Petition to file an ANDA for Imatinib Oral Solution 400 mg/5mL instead of tablets,Proposes new dosage form (oral solution) for patients with swallowing difficulties; no change to drug substance or indication :contentReference[oaicite:4]{index=4}.,
FDA-2012-P-1107-0039_OXIPLEX_SP_Gel__FzioMed__Incorporated_s_Petition_f.pdf,5-Nov-12,"FzioMed, Inc.",N/A,21 CFR 10.33; 21 CFR 814.44,FDA’s denial of premarket approval for OXIPLEX,Request for review and reversal of denial of PMA P070023,Argued data show safety and efficacy for indicated use in lumbar spine surgery; challenged FDA’s evaluation of clinical evidence.
FDA-2012-P-1112-0011_Petition_For_Reconsideration_From_Nobel_Laboratori.pdf,22-Jan-15,"Nobel Laboratories, LLC","Edward J. Petrus, M.D., Medical Director",21 CFR 314.93,Request to allow ANDA for Fasprofen (fast dissolving ibuprofen tablets) instead of Motrin chewable tablets,"Request based on comparable dosage, administration route, therapeutic effect, and published clinical evidence.",
FDA-2012-P-0764-0001_The_Joseph_Dedvukaj_Firm_PC_Citizen_Petition.pdf,12-Jul-12,"The Joseph Dedvukaj Firm, P.C.",N/A,21 C.F.R. § 10.30,FDA approval of Qnexa (Vivus obesity drug),Request FDA to reject or issue Complete Response Letter (CRL) for Qnexa,"Incomplete teratogenicity risk data, cardiovascular risk concerns, insufficient final data from FORTRESS study."
FDA-2012-P-0695-0001_Lorillard_Tobacco_Company__Citizen_Petition.pdf,26-Jun-12,Lorillard Tobacco Company,"Neil L. Wilcox, Senior VP & Chief Compliance Officer","21 U.S.C. §§ 387e(j), 387j; 21 C.F.R. § 10.30",Marketing authorization for new tobacco products,Request FDA to exercise enforcement discretion allowing marketing during SE Report review,Argument based on delays in FDA review process and need for regulatory flexibility for new tobacco products.
FDA-2012-P-1091-0001_Valeant_Pharmaceuticals_International_Inc_Covingto.pdf,31-Oct-12,"Valeant Pharmaceuticals International, Inc.",Submitted via Covington & Burling LLP,21 C.F.R. § 10.30,Withdrawal of certain generic approvals of bupropion XL 300 mg,Require new bioequivalence studies; withdraw approval if necessary,Concerns about non-bioequivalence of generics to Wellbutrin XL 300 mg and patient safety risks.
FDA-2012-P-0738-0001_The_Joseph_Dedvukaj_Firm_PC_Citizen_Petition.pdf,9-Jul-12,"The Joseph Dedvukaj Firm, P.C.",N/A,21 C.F.R. § 10.30,FDA approval of Qnexa (Vivus obesity drug),Request FDA to reject or issue Complete Response Letter (CRL) for Qnexa,Same grounds as other petition: incomplete teratogenicity and cardiovascular safety data.
FDA-2012-P-0872-0001_Handcrafted_Soapmakers_Guild_Inc.pdf,14-May-12,"Handcrafted Soapmakers Guild, Inc.","Leigh O'Donnell, President",15 U.S.C. §1454; 21 CFR Part 701.12,Labeling rules for place of business on cosmetic labels,Amend regulation to allow use of PO Box instead of street address,"Safety and privacy concerns for home-based businesses, changes in data access and communication practices."
FDA-2012-P-0549-0003_Anatase_Biopharmaceutic_Consulting_LLC__Letter.pdf,22-Oct-12,Anatase Biopharmaceutic Consulting LLC,"Alfred T. Elvin, Ph.D.",21 CFR 10.30 (by reference),Change of address for correspondence,N/A,N/A (letter is only an address update for prior petition)
FDA-2012-P-0993-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,13-Sep-12,Sheppard Mullin Richter & Hampton LLP,Peter S. Reichertz,"21 C.F.R. §§ 10.30, 314.93",ANDA suitability for Atropine Sulfate Injection (new strength),Request to allow ANDA for 1.0 mg/ml Atropine Sulfate in glass ampule,"Improved dosing accuracy, minimized preparation errors, and sterility concerns addressed."
FDA-2012-P-0854-0001_B_Braun_Medical_Inc__Citizen_Petition.pdf,2-Aug-12,B. Braun Medical Inc.,"Rebecca Stolarick, Corporate VP of Regulatory Affairs","21 CFR 10.30, 314.93",Designation of Lactated Ringer’s (Hospira) under ANDA 19-416 as RLD,Request FDA to designate Hospira’s product as the RLD for Lactated Ringer’s Irrigation,Supports safe substitution; historic NDA status; minimizes regulatory ambiguity.
FDA-2012-P-0935-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,27-Aug-12,"Lachman Consultant Services, Inc.","Robert Pollock, President","21 CFR 10.30, 314.93",Tadalafil Tablets 40 mg ANDA suitability petition,Request FDA to permit ANDA submission for 40 mg strength,Convenience of dosing; reduce medication errors; aligns with FDA's previous recommendations regarding strength.
FDA-2012-P-0940-0001_Alpharma_LLC_a_Subsidiary_of_Pfizer_Inc_Citizen_Pe.pdf,28-Aug-12,Alpharma LLC (subsidiary of Pfizer Inc.),"Sayed Ahmed, Associate Director, Regulatory Affairs",21 U.S.C. § 360b(n)(3) (Section 512(n)(3) of FDCA),Suitability petition for generic Florfenicol granules for swine drinking water,Permit ANADA submission for granules instead of solution,"Cost efficiency, ease of transport, same therapeutic effectiveness compared to pioneer solution product."
FDA-2012-P-0826-0001_Lachman_Consultant_Services_Inc__Citizen_Petition.pdf,27-Jul-12,"Lachman Consultant Services, Inc.","Robert Pollock, Executive Vice President","21 CFR 10.30, 314.93",Suitability petition for Sitagliptin and Metformin ER Tablets 50 mg/850 mg,Declare suitability for ANDA submission,Provides additional dosing flexibility while maintaining dosage safety and efficacy ranges of the RLD (Janumet XR).
FDA-2012-P-0964-0001_Lannett_Company_Inc_Citizen_Petition.pdf,5-Sep-12,"Lannett Company, Inc.","Arthur Bedrosian, President and CEO",21 CFR § 314.93,Request to allow ANDA submission for lower acetaminophen strength Hydrocodone Bitartrate/Acetaminophen tablets,"Permit ANDAs for 2.5/250 mg, 3.75/250 mg, 5/250 mg, and 3.75/325 mg strengths",Supports safer acetaminophen dosing per FDA acetaminophen policy; therapeutic equivalence maintained.
FDA-2012-P-0299-0005_Front_Range_Equine_Rescue_FRER_and_The_Humane_Soci.pdf,24-Aug-12,Front Range Equine Rescue and The Humane Society of the United States,"Bruce A. Wagman, Schiff Hardin LLP","21 CFR Part 10 (general); Food, Drug, and Cosmetic Act sections addressing adulteration",Prohibit sale of horse meat from U.S. horses for human consumption,Health risks from untraceable drug exposure in horses not raised for food; FDA warning letters cited as evidence.,
FDA-2012-P-0496-0004_Cumberland_Pharmaceuticals_Inc__Amendment.pdf,9-Jul-12,Cumberland Pharmaceuticals Inc.,"Amy D. Rock, Ph.D., Senior Director, Regulatory & Scientific Affairs",21 CFR 314.93,Request to allow ANDA for lactulose crystals 10g and 20g for treatment of portal systemic encephalopathy,Permit ANDA using liquid lactulose RLD; dosage form change justified by equivalent clinical effect and precedent.,
FDA-2012-P-0260-0024_Fisher_Wallace___CP_Amendment__2.pdf,17-Jan-17,"Fisher Wallace Laboratories, LLC","Kelly Roman, Co-Founder",21 CFR Part 10 (by reference),FDA reclassification and regulatory actions regarding Cranial Electrotherapy Stimulators (CES),Request reconsideration of CES device reclassification; challenge findings of OSI report,Alleged bias and irregularities in FDA proceedings; insufficient investigation of concerns raised in original petition.
FDA-2012-P-0986-0003_Sheppard_Mullin_Richter_Hampton_LLP_Supplement.pdf,6-Feb-13,Sheppard Mullin Richter & Hampton LLP,Peter S. Reichertz,"21 C.F.R. §§ 10.30, 314.93 (supplementing original petition)","ANDA suitability for Atropine Sulfate Injection, 1.0 mg/mL (Glass Ampules)",Amend prior citizen petition to revise labeling and address FDA comments,"Revised pediatric labeling, corrected description inconsistencies, addressed excipient matching, and dosage calculations to align with RLD standards."
FDA-2012-P-0617-0001_Combination_Products_Coalition_CPC_Esptein_Becker_.pdf,8-Jun-12,"Combination Products Coalition (via Epstein Becker & Green, P.C.)","Bradley Merrill Thompson, Counsel",21 C.F.R. § 10.20,Transparency and guidance improvements for FDA's handling of combination products,"Streamline guidance processes, publish more regulatory decisions, and enhance stakeholder engagement","Improve regulatory efficiency, public access, and support innovation in combination products."
FDA-2012-P-0647-0001_Laboratorios_SALVAT_SA_Fish_and_Richardson_PC_Citi.pdf,19-Jun-12,"Laboratorios SALVAT, S.A. (via Fish & Richardson P.C.)",N/A,21 U.S.C. § 355; 21 C.F.R. § 314,Refusal of ANDAs proposing non-sterile generics citing CETRAXAL®,Prevent approval of non-sterile generics based on labeling and safety risks,Differences in sterility would require improper label changes; risk of middle ear infections in patients.
FDA-2012-P-1112-0001_Nobel_Laboratories_LLC_Citizen_Petition.pdf,21-Oct-12,"Nobel Laboratories, LLC","Edward J. Petrus, M.D., Medical Director",21 CFR § 314.93,"ANDA suitability petition for Fasprofen, Orally Disintegrating Tablets 100 mg",Allow ANDA for orally disintegrating form of Motrin 100 mg chewable tablets,Provides alternative dosage form for ease of use; similar absorption profile; maintains therapeutic effect.
FDA-2012-P-0554-0001_Lupin_Pharmaceuticals_Inc__Citizen_Petition.pdf,1-Jun-12,"Lupin Pharmaceuticals, Inc.","Leslie Sands, Director – Regulatory Affairs (USA)",21 CFR 314.161,Determination regarding discontinuation of LOFIBRA® (Fenofibrate Tablets) 54 mg and 160 mg,Request FDA to determine if discontinuation was not for safety or effectiveness reasons,To permit ANDA submissions using LOFIBRA® as RLD if safe; continuation of generic market access.
FDA-2012-P-0549-0001_Anatase_Biopharmaceutic_Consulting_LLC_Citizen_Pet.pdf,24-May-12,Anatase Biopharmaceutic Consulting LLC,"Alfred T. Elvin, Ph.D.",21 U.S.C. § 355,Prevent approval of Calcitriol Capsule generics not demonstrating fasting and fed bioequivalence,Request FDA to require BE studies under fasting and fed conditions for therapeutic equivalence,Safety risks if bioequivalence not properly demonstrated under different physiological conditions.
FDA-2012-P-1127-0001_Onco_Therapies_Limited_Strides_Inc_Citizen_Petitio.pdf,7-Nov-12,Onco Therapies Limited / Strides Inc.,"Anil Sachdeva, Assistant Vice President - Regulatory Affairs","21 CFR 10.30, Section 505(j)(2)(C) of FDCA","Request for ANDA suitability for Docetaxel Injection, 20 mg/mL in 8 mL fill",Seek designation of Accord Healthcare’s product (N201195) as RLD to allow ANDA submission,Product is qualitatively and quantitatively the same; request full waiver of pediatric study requirements.
FDA-2012-P-1058-0001_Lachman_Consultant_Sevices_Inc_Citizen_Petition.pdf,10-Oct-12,"Lachman Consultant Services, Inc.",On behalf of client (name not disclosed),"21 CFR 10.30, Section 505(j)(2)(C) of FDCA","Request ANDA suitability for Mefenamic Acid Capsules, USP, 500 mg",Change in strength from RLD (PONSTEL® 250 mg) justified by labeling dosage instructions,Single 500 mg capsule improves dosing accuracy and compliance.
FDA-2012-P-1029-0001_Citizen_Petition_from_Lachman_Consultant_Services_.pdf,24-Sep-12,"Lachman Consultant Services, Inc.",On behalf of client (name not disclosed),"21 CFR 10.30, Section 505(j)(2)(C) of FDCA","Request ANDA suitability for Valrubicin Solution for Intravesical Instillation, 800 mg/20 mL vial",Increase in total drug content (same concentration) justified to improve convenience and reduce waste,"Same concentration, route, inactive ingredients; lower contamination risk."
FDA-2012-P-0997-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,14-Sep-12,Sheppard Mullin Richter & Hampton LLP,"Peter S. Reichertz, Partner","21 CFR 10.30, 314.93",Request ANDA suitability for Magnesium Sulfate Injection 50% in 2 mL and 10 mL glass vials,Change from plastic to glass containers for Magnesium Sulfate Injection NDA 019316,Container material change poses no safety issues; meets USP standards.
FDA-2012-P-0945-0001_Center_for_Regulatory_Servics__Inc__Citizen_Petiti.pdf,29-Aug-12,"Center for Regulatory Services, Inc.","Kristi O. Smedley, Ph.D., Vice President","21 CFR 10.30, Section 512(n)(3)(A) of FDCA (Animal Drug)",Request ANADA suitability for Pimobendan 10 mg chewable tablets for dogs,Provides dosing convenience for large dogs; maintains proportional composition and therapeutic equivalence.,
FDA-2012-P-0904-0001_Citizen_for_Health_Citizen_Petition.pdf,15-Aug-12,Citizens for Health,"James S. Turner, Board Chair","21 U.S.C. 321(s), 342, 348, and 371",Regulation of high fructose corn syrup concentrations above 55%,Request amendments to 21 CFR 184.1866 to require labeling of fructose concentration; enforcement against non-GRAS HFCS products,"Consumer protection, prevent mislabeling, uphold GRAS safety standards."
FDA-2012-P-1147-0001_Foley_Lardner_LLP_Citizen_Petition.pdf,13-Nov-12,Foley & Lardner LLP (on behalf of client),"David L. Rosen, Esq.","21 CFR 10.30, 314.93","Request ANDA suitability for Dexmedetomidine Hydrochloride Injection, 400 mcg/4 mL vial",Allow different fill volume (not concentration change) compared to PRECEDEX®,No changes to strength or safety profile; improved convenience for healthcare providers.
FDA-2012-P-0989-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,13-Sep-12,Sheppard Mullin Richter & Hampton LLP,Peter S. Reichertz,"21 CFR 10.30, 314.93","Request ANDA suitability for Sodium Acetate Injection, USP 2 mEq/mL in 20 mL glass vial",Change container material from plastic to glass for existing RLD,Glass containers are more stable; no safety or efficacy concerns; no bioequivalence testing needed&#8203;:contentReference[oaicite:0]{index=0}.
FDA-2012-P-0982-0001_Sheppard_Mullin_Richter_and_Hampton_LLP_Citizen_Pe.pdf,13-Sep-12,Sheppard Mullin Richter & Hampton LLP,"Peter S. Reichertz, Partner","21 CFR 10.30, 314.93","Request ANDA suitability for Sodium Acetate Injection, USP 4 mEq/mL",Approval to file ANDA for new strength and volume (glass vial) vs RLD,"Improves convenience, reduces waste, no safety concerns&#8203;:contentReference[oaicite:0]{index=0}."
FDA-2012-P-0906-0001_Lachman_Consultant_Services_Inc.pdf,15-Aug-12,"Lachman Consultant Services, Inc.","Joan Janulis, Vice President",21 CFR 10.30,Request to designate Absorica™ as separate RLD for isotretinoin capsules,Allow ANDAs referencing Absorica due to bioavailability differences from Amnesteem™,Absorica not bioequivalent to Amnesteem™ under fasting conditions&#8203;:contentReference[oaicite:1]{index=1}.
FDA-2012-P-0698-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,27-Jun-12,"Lachman Consultant Services, Inc.",Robert W. Pollock,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30 and 314.93,"Request for suitability determination to submit an ANDA for Metoprolol Succinate Extended-release Tablets, 12.5 mg",Provide an accurate 12.5 mg tablet strength for heart failure patients instead of requiring tablet splitting :contentReference[oaicite:0]{index=0}.,
FDA-2012-P-0496-0001_Cumberland_Pharmaceuticals_Inc_Citizen_Petition.pdf,17-May-12,Cumberland Pharmaceuticals Inc.,"Amy D. Rock, PhD","Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30, 314.93",Request for permission to file an ANDA for lactulose crystals (KRISTALOSE®) based on ENULOSE® Liquid RLD,Proposed reconstitution to oral solution preserves intended use and efficacy; crystals offer dosing flexibility :contentReference[oaicite:1]{index=1}.,
FDA-2012-P-0992-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,13-Sep-12,Sheppard Mullin Richter & Hampton LLP,"Peter S. Reichertz, Esq.",Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30 and 314.93,"ANDA Suitability Petition for Potassium Acetate Injection, USP, 4 mEq/mL, 50 mL glass vial",Change strength and container from 2 mEq/mL 20 mL plastic vial to 4 mEq/mL 50 mL glass vial to improve hospital convenience :contentReference[oaicite:2]{index=2}.,
FDA-2012-P-0994-0001_Sheppard_Mullin_Richter_Hampton_LLP_Citizen_Petiti.pdf,13-Sep-12,Sheppard Mullin Richter & Hampton LLP,"Peter S. Reichertz, Esq.",Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30 and 314.93,"ANDA Suitability Petition for Sodium Acetate Injection, USP, 2 mEq/mL, 100 mL glass vial",Request to submit ANDA for larger volume glass vial version of Sodium Acetate to reduce waste :contentReference[oaicite:0]{index=0}.,
FDA-2012-P-0153-0001_Intertek_Citizen_Petition.pdf,10-Feb-12,Intertek,"Paula Wilkerson, RAC, CRA",Section 523 of the FD&C Act; 21 CFR 10.30,Request FDA to refrain from dismissing Intertek as Accredited Person for 510(k) Review without due process,Request reinstatement as Accredited Person and completion of Biophotas 510(k) review :contentReference[oaicite:0]{index=0}.,
FDA-2012-P-1034-0001_Lachman_Consultant_Sevices_Inc_Citizen_Petition.pdf,27-Sep-12,"Lachman Consultant Services, Inc.",Paul J. Schwartz (Vice President),21 CFR 10.30 and 314.161,Request for determination whether SUBOXONE Sublingual Tablets were withdrawn for safety or effectiveness,Request supports approval of ANDAs referencing SUBOXONE tablets :contentReference[oaicite:1]{index=1}.,
FDA-2012-P-0478-0001_Xspire_Pharma_LLC_Citizen_Petition.pdf,7-May-12,"Xspire Pharma, LLC","F. Randy Lloyd, CEO",Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93,ANDA Suitability Petition for reformulated Pentazocine and Acetaminophen tablets,Request to allow ANDA submission for Acetaminophen 312.5 mg and Pentazocine Hydrochloride 25 mg tablets to comply with acetaminophen limits :contentReference[oaicite:0]{index=0}.,
FDA-2012-P-1068-0001_Ben_Venue_Laboratories_Inc_Citizen_Petition.pdf,12-Oct-12,"Ben Venue Laboratories, Inc.","Amy Schutte (Associate Director, Regulatory Affairs)",Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93 and 10.30,Request ANDA suitability for new strength of Ondansetron in 5% Dextrose Injection (16 mg/25 mL),Reduce overdose risk based on FDA drug safety communication about QT prolongation; facilitate safer dosing :contentReference[oaicite:1]{index=1}.,
FDA-2012-P-1251-0001_Gordon_Johnston_Regulatory_Consultants_LLC_Citizen.pdf,17-Dec-12,"Gordon Johnston Regulatory Consultants, LLC",Gordon Johnston (Principal),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30,"Request ANDA suitability for Morphine Sulfate Injection USP, 5 mg/mL, single-use vial",Intermediate strength requested for better dosing flexibility compared to 4 mg/mL RLD :contentReference[oaicite:2]{index=2}.,
FDA-2012-P-0589-0002_Onco_Therapies_Limited_Strides_Inc_Citizen_Petitio.pdf,4-Jun-12,Onco Therapies Limited / Strides Inc.,Anil Sachdeva (U.S. Agent),Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.30,Request FDA to allow submission of ANDA for Docetaxel Injection 20 mg/mL in 8 mL fill,Request based on maintaining the same concentration while increasing the fill volume to 160 mg/8mL :contentReference[oaicite:0]{index=0}.,
FDA-2012-P-0497-0001_Piedmont_Animal_Health_Citizen_Petition.pdf,17-May-12,Piedmont Animal Health,"Kathleen G. Palma, Ph.D. (Vice President, Research, Development, and Regulatory)",Section 512(n)(3) of the FD&C Act,"ANDA Suitability Petition for a generic soft chewable form of enrofloxacin differing in texture, hardness, and size from Baytril® Taste Tabs® :contentReference[oaicite:0]{index=0}.",,
FDA-2012-P-1158-0001_Milagros_Demier_Citizen_Petition.pdf,20-Nov-12,Milagros Demier,N/A,21 CFR 10.30,Petition to deny release of genetically modified mosquitoes in Key West,"Cites environmental, health, and economic risks if GM mosquitoes are released :contentReference[oaicite:0]{index=0}.",
FDA-2012-P-0775-0001_Xspire_Pharma_LLC_Citizen_Petition.pdf,12-Jul-12,"Xspire Pharma, LLC",Ford J. Mundy (President & CEO),21 CFR 314.93,"Request to file ANDA for Acetaminophen, Caffeine, Dihydrocodeine Bitartrate Tablets with reduced acetaminophen content (312.5 mg) to comply with FDA safety guidance :contentReference[oaicite:1]{index=1}.",,
FDA-2012-P-0497-0001_Piedmont_Animal_Health_Citizen_Petition.pdf,17-May-12,Piedmont Animal Health,"Kathleen G. Palma, Ph.D.",Section 512(n)(3) of the FD&C Act,ANDA Suitability Petition for generic enrofloxacin soft chewable differing in texture and hardness :contentReference[oaicite:2]{index=2}.,,
FDA-2012-P-0458-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,7-May-12,"Lachman Consultant Services, Inc.",Robert W. Pollock,21 CFR 10.30 and 314.161,"Request FDA to determine whether Aloxi® (palonosetron hydrochloride) Capsules, 0.5 mg were withdrawn for reasons of safety or effectiveness :contentReference[oaicite:0]{index=0}.",,
FDA-2012-P-1179-0001_Jack_M_Saroyan_DDS_Citizen_Petition.pdf,24-Nov-12,"Jack M. Saroyan, DDS",N/A,21 CFR 10.30,Request to permit addition of fluoride to iodized table salt to prevent iodine deficiency and dental caries :contentReference[oaicite:1]{index=1}.,,
FDA-2012-P-1104-0001_Lachman_Consultant_Services_Inc_Citizen_Petition.pdf,2-Nov-12,"Lachman Consultant Services, Inc.",Robert W. Pollock,21 CFR 10.30 and 314.161,Request FDA determination whether Juvisync™ (sitagliptin and simvastatin) Tablets (various strengths) were withdrawn for safety or effectiveness reasons :contentReference[oaicite:0]{index=0}.,,
FDA-2012-P-0607-0001_AIDS_Healthcare_Foundation_AHF_Citizen_Petition.pdf,8-Jun-12,AIDS Healthcare Foundation (AHF),Tom Myers (General Counsel),Section 505(q) of the FD&C Act; 21 CFR 10.30,Request FDA not rely on Antiviral Drugs Advisory Committee's recommendation regarding Gilead’s Truvada® for PrEP; request reconvening a fairly balanced committee :contentReference[oaicite:0]{index=0}.,,
FDA-2012-P-1071-0001_Law_Office_of_Alvin_J_Lorman_Citizen_Petition.pdf,12-Oct-12,Law Office of Alvin J. Lorman,Alvin J. Lorman,21 CFR 10.30 and 314.122,Request FDA determination that Geref (sermorelin acetate) NDA No. 020443 was withdrawn for reasons other than safety or efficacy :contentReference[oaicite:1]{index=1}.,,
FDA-2012-P-0895-0003_Endo_Pharmaceuticals_Inc_Supplement.pdf,13-Nov-12,Endo Pharmaceuticals Inc.,"Robert Barto (Vice President, Regulatory Affairs)",21 CFR 10.30,Supplement to Citizen Petition providing confidential attachments regarding Opana ER reformulation and abuse data :contentReference[oaicite:0]{index=0}.,,
FDA-2012-P-0916-0001_Call_Inc_dba_Rochester_Pharmaceuticals_Ei_Inc__Cit.pdf,16-Aug-12,Call Inc. (dba Rochester Pharmaceuticals) via Ei Inc.,Edward Patt (Director Regulatory Affairs),"Section 505(j)(2)(C) of the FD&C Act; 21 CFR 10.20, 10.30, 314.122",Request FDA determination that Differin™ (adapalene solution) 0.1% was not withdrawn for safety or effectiveness; enable ANDA submission :contentReference[oaicite:0]{index=0}.,,
FDA-2012-P-0431-0001_Alcon_Research_Ltd_Citizen_Petition.pdf,1-May-12,Alcon Research Ltd.,Nancy Cariker-Moon,Section 505(a) of the FD&C Act; 21 CFR 10.30,Request FDA to take enforcement action against unapproved pilocarpine HCl ophthalmic solutions competing with ISOPTO® Carpine products :contentReference[oaicite:0]{index=0}.,,
FDA-2012-P-1189-0012_Bee_Chicken_of_the_Sea_Starkist__TMP_Application_A.pdf,2-Feb-12,"Bumble Bee Foods, LLC; StarKist Co.; Tri-Union Seafoods, LLC","Robert A. Hahn, Esq.",21 CFR 130.17,"Amendment to Temporary Marketing Permit Application for canned tuna deviating from identity standard by using drained weight rather than pressed cake weight, and requesting exemption from substandard fill labeling :contentReference[oaicite:0]{index=0}.",,
FDA-2012-P-1259-0001_Hyman_Phelps_McNamara_PC_Citizen_Petition.pdf,21-Dec-12,"Hyman, Phelps & McNamara, P.C.",Kurt R. Karst,Section 505(j)(2)(C) of the FD&C Act; 21 CFR 314.93,"Request FDA approval to file an ANDA for Pemetrexed Disodium for Injection, 750 mg/vial, based on change in strength from ALIMTA 500 mg/vial :contentReference[oaicite:0]{index=0}.",,
FDA-2012-P-0462-0001_Douglass_Oeller_Consulting_Inc_Citizen_Petition.pdf,7-May-12,"Douglass Oeller Consulting, Inc.","Douglass S. Oeller, DVM",Section 512(n)(3) of the FD&C Act,Request permission to file an ANADA for a generic hyaluronate sodium injection for horses with different strength (17 mg/mL) and packaging (pre-filled syringe) compared to pioneer Legend® (10 mg/mL vials) :contentReference[oaicite:1]{index=1}.,,
FDA-2012-P-0916-0003_Call_Inc_dba_Rochester_Pharmaceuticals_Ei_Inc__Ame.pdf,23-Aug-12,Call Inc. (dba Rochester Pharmaceuticals) via Ei Inc.,"Edward Patt (Director, Regulatory Affairs)",21 CFR 10.30 and 314.122,Request FDA determination whether Differin (adapalene solution) 0.1% was withdrawn for reasons other than safety or effectiveness :contentReference[oaicite:2]{index=2}.,,
FDA-2012-P-0589-0003_OncoTherapies_Limited_Withdrawal.pdf,5-Nov-12,Onco Therapies Limited (via Strides Inc.),"Anil Sachdeva, Assistant Vice President - Regulatory Affairs",21 CFR 10.30 (implicit),Withdrawal of Citizen Petition for Docetaxel Injection 20 mg/mL 8mL fill,Withdraw petition because the referenced Accord Healthcare product was approved before petition action needed&#8203;:contentReference[oaicite:0]{index=0}.,
FDA-2012-P-1043-0001_Foley_Lardner_LLP_Citizen_Petition.pdf,2-Oct-12,Foley & Lardner LLP,"David L. Rosen, B.S. Pharm., J.D.","21 CFR 10.30, 314.93",Request FDA to designate Medefil’s Sodium Chloride Injection in prefilled syringes as a second RLD,Facilitate generic competition for prefilled syringe format; same active ingredient and concentration&#8203;:contentReference[oaicite:0]{index=0}.,
FDA-2012-P-1128-0003_Dechra_Ltd_Citizen_Petition.pdf,23-Oct-12,Dechra Ltd.,"Susan L. Longhofer, DVM, MS, Dip. ACVIM",21 CFR 512(n)(3),Request permission to file ANADA for pimobendan tablets (different scoring),Scoring tablets into quarters (instead of halves) improves dosing flexibility for dogs&#8203;:contentReference[oaicite:1]{index=1}.,
FDA-2012-P-1128-0001_Dechra_Ltd_Citizen_Petition.pdf,23-Oct-12,Dechra Ltd.,"Susan L. Longhofer, DVM, MS, Dip. ACVIM",21 CFR 512(n)(3),Request permission to file ANADA adding 10 mg tablet size for pimobendan,Enhanced dosing convenience for larger dogs while maintaining therapeutic equivalence&#8203;:contentReference[oaicite:2]{index=2}.,
FDA-2012-P-1267-0003_Xspire_Pharma_LLC_Withdrawal_of_Petition.pdf,9-Jul-13,Xspire Pharma LLC,"Richard J. Mundy, President and CEO",21 CFR 10.30 (by reference),Withdrawal of suitability petition for Hydrocodone Bitartrate 5mg and Aspirin 325mg tablets,Voluntary withdrawal; prior email to FDA incomplete; now properly sent&#8203;:contentReference[oaicite:0]{index=0}.,
FDA-2012-P-1180-0001_Lannett_Company_Inc_Citizen_Petition.pdf,26-Nov-12,"Lannett Company, Inc.","Arthur P. Bedrosian, President and CEO",21 CFR 314.93,Request ANDA suitability for Oxycodone Hydrochloride Extended-Release Capsules (instead of tablets),"Request based on solid oral dosage similarity, expected therapeutic equivalence&#8203;:contentReference[oaicite:0]{index=0}.",
FDA-2012-P-1104-0003_Lachman_Consultant_Services_Inc.pdf,17-Dec-12,"Lachman Consultant Services, Inc.","Robert W. Pollock, Executive Vice President","21 CFR 10.30, Section 505(j)(2)(C)",Withdrawal of petition regarding Juvisync (sitagliptin/simvastatin) NDA marketing status,Withdrawn because products commenced marketing&#8203;:contentReference[oaicite:0]{index=0}.,
FDA-2012-P-0915-0004_Sunovion_Pharmaceticals_Inc_Covington__Burling_LLP.pdf,30-Aug-12,"Sunovion Pharmaceuticals, Inc. (via Covington & Burling LLP)","Peter O. Safir, Counsel",21 CFR 10.30,Request to withdraw previously filed citizen petition and confidential supplement,Withdrawal of August 16 and August 21 submissions after superseding filing&#8203;:contentReference[oaicite:0]{index=0}.,
FDA-2012-P-1180-0003_Lannett_Co_Inc_Amendment_to_Suitability_Petition.pdf,17-Dec-12,"Lannett Company, Inc.","Arthur P. Bedrosian, President and CEO",21 CFR 10.30 (Amendment),Amendment to earlier suitability petition regarding Oxycodone ER Capsules,Provides PREA waiver request; clarifies tamper-resistance compliance; removes bioequivalence determination request&#8203;:contentReference[oaicite:1]{index=1}.,
FDA-2012-P-1034-0004_Reference_1_Further_US_RB_Pharmaceuticals_Announce.pdf,25-Sep-12,Reckitt Benckiser Pharmaceuticals Inc.,"Richard Simkin, President",21 CFR 10.30,"Request FDA to mandate pediatric safety measures for buprenorphine products (unit-dose packaging, educational campaigns)",Based on increased pediatric exposures with Suboxone Tablets compared to Film; child-safety packaging reduces risk&#8203;:contentReference[oaicite:0]{index=0}.,
FDA-2012-P-0738-0003_The_Joseph_Dedvukaj_Firm_P_C_Withdrawal_of__Citize.pdf,12-Jul-12,"The Joseph Dedvukaj Firm, P.C.","Joseph Dedvukaj, Attorney",21 CFR 10.30 (withdrawal letter),Withdrawal of earlier citizen petition regarding Qnexa drug candidate,Clerical errors in original petition prompted withdrawal and resubmission&#8203;:contentReference[oaicite:0]{index=0}.,
FDA-2012-P-0545-0003_Pfizer_Inc__Withdrawal_of_Citizen_Petition.pdf,6-Jun-12,Pfizer Inc.,"Geoffrey Levitt, Senior VP & Associate General Counsel","21 U.S.C. § 351, § 355; 21 CFR 10.30",Withdrawal of prior citizen petition (FDA-2012-P-0545),Request to withdraw original petition and submit a revised petition with amended certification section&#8203;:contentReference[oaicite:0]{index=0}.,
FDA-2012-P-1189-0009_Canned_Tuna_Deviating_From_Identity_Standard__Temp.pdf,27-Aug-14,"Bumble Bee Foods, LLC","Steven Mavity (Senior Vice President, Technical Services & Corporate Quality)",21 CFR 130.17,Label approvals for canned tuna products under Temporary Market Permit; certain products discontinued :contentReference[oaicite:0]{index=0}.,,
FDA-2012-P-1028-0010_Safety_Concerns_Regarding_Buprenorphine_for_Opioid.pdf,20-Nov-12,Reckitt Benckiser (referenced by FDA),N/A,21 CFR 10.30,Safety concerns related to accidental pediatric exposure to buprenorphine products,Request clarification and evaluation of pediatric risks,Concerns about pediatric exposure and lack of safeguards :contentReference[oaicite:0]{index=0}.